Linaprazan

Linaprazan (AZD0865) can inhibit H+, K+ -ATPase in the stomach through K+ competitive binding, (IC50: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) can be used for research on reflux esophagitis with oral activity[1][2][3].

Product Specifications

CAS Number

[248919-64-4]

Product Name Alternative

AZD0865

UNSPSC

12352005

Hazard Statement

H302-H315-H319

Target

Proton Pump

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AZD0865.html

Concentration

10mM

Purity

98.80

Solubility

DMSO : ≥ 35 mg/mL

Smiles

O=C(C1=CN2C(C(NCC3=C(C)C=CC=C3C)=C1)=NC(C)=C2C)NCCO

Molecular Formula

C21H26N4O2

Molecular Weight

366.46

Precautions

P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Gedda K et al. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+, K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73 (2) :198-205.|[2]Kahrilas PJ et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007 Dec;5 (12) :1385-91.|[3]Xinyue Zhang, et al. Absorption, distribution, metabolism and excretion of linaprazan glurate in rats. J Pharm Biomed Anal. 2024 May 15:242:116012.